AUSTIN, Texas--(BUSINESS WIRE)--Mirna Therapeutics, Inc. announced today that the USPTO has allowed claims related to the therapeutic application of let-7 in the regulation of oncogenes. The claims derive from a patent application that was submitted by Yale University and exclusively licensed to Mirna related to the pioneering work of Dr. Frank Slack, Professor of Molecular, Cellular & Developmental Biology at Yale University in New Haven, CT. Let-7 was the first miRNA that was demonstrated to function as a tumor suppressor via its ability to regulate oncogene expression.
